| 영문 | carcinoembryonic antigen | 한글 | 암배아항원 |
|---|---|---|---|
| 설명 | 원래 태아의 장조직에서 정상적으로 존재하는 물질로 태아기 이후에는 존재하지 않는 물질이다. 그러나 위, 간, 허파 등의 암이 있는 경우에 성인에서도 존재한다. 이를 이용해서 암의 치료효과 판정이나 재발여부의 조사에 이용한다. |
||
| 영문 | antigen | 한글 | 항원 |
|---|---|---|---|
| 설명 | 특이한 면역반응을 일으킬 수 있는 어떠한 물질. 여기에서 말하는 특이한 면역반응이란 비특이적인 면역반응과는 반대되는 의미로 그 물질에 대해서 특이하게 반응할 수 있는 항체나 그 물질에 대해서 특이하게 반응할 수 있는 세포를 만드는 것을 말한다. |
||
| HLA | histocompatibility leukocyte antigen; histocompatibility locus antigen; homologous leukocyte antibod... |
|---|---|
| TSA | technical surgical assistance; toluene sulfonic acid; total shoulder arthroplasty; total solute abso... |
| TSTA | toxoplasmin skin test antigen; tumor-specific tissue antigen; tumor-specific transplantation antigen... |
| CEA | Carcino-Embryonic Antigen [HP 1825-6] ; Oncofetal Antigens ; Glycopro... |
| AA | abdominal aorta; acetic acid; achievement age; active alcoholic; active assistive [range of motion];... |
| T-antigen | Thomsen Friedenreich antigen |
|---|---|
| T-antigen | Tumor antigen |
| ATLA | ATL-associated antigen |
| ATLA | Adult T-cell leukemia-associated antigen |
| AWA | Adult worm antigen |
| haptenic inhibition | <immunology, molecular biology> Could be considered an isolated epitope: although a hapten (by definition) has an antibody directed against it, the hapten alone will not induce an immune response if injected into an animal, it must be conjugated to a carrier (usually a protein). The hapten constitutes a single antigenic determinant, perhaps the best known example is dinitro phenol (DNP) that can be conjugated to BSA and against which antiDNP antibodies are produced (antibodies to the BSA can be adsorbed out). Because the hapten is monovalent, immune complex formation will be blocked if the soluble hapten is present as well as the hapten carrier conjugate (assuming there is more than one hapten per carrier then an immune precipitate can be formed). Competitive inhibition by the soluble small molecule is sometimes referred to as haptenic inhibition and this term has carried over into lectin mediated haemagglutination where monosaccharides are added to try to block haemagglutination: the blocking sugar defines the specificity of the lectin. (18 Nov 1997) |
|---|---|
| acetone-insoluble antigen | A diphosphatidyl glycerol that is found in the membrane of Treponema pallidum and is the antigen detected by the Wasserman test for syphilis. (18 Nov 1997) |
| allogeneic antigen | Genetic variations of the same antigens within a given species. (05 Mar 2000) |
| antigen | Virus coded cell surface antigens that appear soon after the infection of a cell by virus, but before virus replication has begun. See: early gene. (18 Nov 1997) |
| antigen-antibody complex | The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble. Immune complexes activate complement through the classical pathway. See: glomerulonephritis, Arthus reaction, type III hypersensitivity. (12 Dec 1998) |
| antigen-antibody reaction | The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin. See: skin test. (05 Mar 2000) |
| antigen-binding site | <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope). Also used of the site on a ligand molecule to which a cell surface receptor binds. (18 Nov 1997) |
| antigen-combining site | See: paratope. (05 Mar 2000) |
| antigen excess | In a precipitation test, the presence of uncombined antigen above that required to combine with all of the antibody; precipitation may be inhibited because the presence of excess antigen gives rise to soluble antigen-antibody complexes, in vivo the resultant antigen-antibody interaction in such an antigen excess may give rise to immune complexes, which have a potential to induce cellular damage; such injury underlies the pathologic changes seen in certain immune complex diseases. (05 Mar 2000) |
| antigen interferon | <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation. This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity. Synonym: antigen interferon, immune interferon. Pharmacological action: antineoplastic agent, antiviral agents. (20 Sep 2002) |
| antigen p150,95 | A major adhesion-associated heterodimer molecule expressed by human monocytes, granulocytes, nk cells, and some lymphocytes. The alpha subunit is the CD11c antigen (also called leu-m5), a surface antigen expressed on some myeloid cells. The beta subunit is the CD18 antigen (antigens, CD18). The p150,95 antigen has been shown to play an important role in cell-cell and cell-substrate adhesive interactions. (12 Dec 1998) |
| antigen presentation | A cell that carries on its surface antigen bound to MCH Class I or Class II molecules and presents the antigen in this context to T-cells. Includes macrophages, endothelium, dendritic cells and Langerhans cells of the skin. See: MHC restriction, histocompatibility antigens. (18 Nov 1997) |
| antigen presenting cell | A cell that carries on its surface antigen bound to MCH Class I or Class II molecules and presents the antigen in this context to T-cells. Includes macrophages, endothelium, dendritic cells and Langerhans cells of the skin. See: MHC restriction, histocompatibility antigens. (18 Nov 1997) |
| antigen-presenting cells | Immunocompetent cells, usually ia positive, that mediate the cellular immune response by processing and presenting antigens or mitogens which stimulate T-cell activation. (12 Dec 1998) |
| antigen processing | Modification of an antigen by accessory cells. This usually involves endocytosis of the antigen and either minimal cleavage or unfolding. The processed antigen is then presented in modified form by the accessory cell. (18 Nov 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|